The Experts below are selected from a list of 138309 Experts worldwide ranked by ideXlab platform
Valentin Fuster - One of the best experts on this subject based on the ideXlab platform.
-
maximizing therapeutic envelope for prevention of cardiovascular disease role of polypill
Mount Sinai Journal of Medicine, 2012Co-Authors: Gines Sanz, Valentin FusterAbstract:Cardiovascular-disease prevention is often inadequate due to several factors. Lack of professional Adherence to guidelines, unaffordable medication, and lack of patients' Adherence to Treatment are the most important. It has been suggested that an affordable, fixed-dose combination drug containing evidence-based active compounds could improve cardiovascular prevention by improving patients' Adherence to Treatment. The available evidence suggests that the polypill strategy can achieve this objective and it will gain a place in the therapeutic armamentarium for the prevention of cardiovascular events in patients at high risk. Mt Sinai J Med 79:683–688, 2012. © 2012 Mount Sinai School of Medicine
-
the fixed dose combination drug for secondary cardiovascular prevention project improving equitable access and Adherence to secondary cardiovascular prevention with a fixed dose combination drug study design and objectives
American Heart Journal, 2011Co-Authors: Gines Sanz, Valentin Fuster, Luis A Guzman, Antonio Guglietta, Joan Albert Arnaiz, Felipe Martinez, Antonio Sarria, Maria Carla Roncaglioni, Kathryn TaubertAbstract:In spite of advances in prevention and Treatment, the burden of cardiovascular diseases is increasing. A fixed-dose combination (FDC) pill, or “polypill,” composed of evidence-based drugs has been proposed as a means of improving cardiovascular prevention by reducing cost and increasing patient Adherence to Treatment. The aim of the FOCUS project, funded by the 7th Framework Programme of the European Commission, is to characterize the factors that underlie inadequate secondary prevention and to test a new FDC. to achieve these goals, a 9-member consortium has been constituted, including institutions from Argentina, France, Italy, Spain, and Switzerland. FOCUS Phase-1 will examine factors potentially related to lack of adequate secondary prevention in 4,000 post–myocardial infarction (MI) patients and analyze the relationship between these factors and patient Treatment Adherence. Primary end points will be (1) the percentage of patients receiving aspirin, angiotensin-converting enzyme inhibitors, and statins and (2) Adherence to Treatment measured by the Morisky-Green test. FOCUS Phase-2 is a randomized trial that will compare Adherence to Treatment in 1,340 post–myocardial infarction patients either receiving an FDC comprising aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and simvastatin (40 mg) or receiving the same 3 drugs separately.
-
fixed dose combination therapy and secondary cardiovascular prevention rationale selection of drugs and target population
Nature Reviews Cardiology, 2009Co-Authors: Gines Sanz, Valentin FusterAbstract:Ischemic heart disease and stroke are the leading causes of death worldwide. A large proportion of individuals at high 10-year risk of a cardiovascular event live in low-income and middle-income countries, and the large majority of all cardiovascular events occur in developing countries. A large amount of evidence supports the use of pharmacological Treatment for the prevention of cardiovascular death in this population, including antiplatelet drugs, beta blockers, lipid-lowering agents and angiotensin-converting-enzyme inhibitors. However, the efficacy of cardiovascular prevention is hampered by several problems, including inadequate prescription of medication, poor Adherence to Treatment, limited availability of medications and unaffordable cost of Treatment. Here we examine the use of fixed-dose combination therapy (a 'polypill'), and how this therapy could improve Adherence to Treatment, reduce the cost and improve Treatment affordability in low-income countries.
John Weinman - One of the best experts on this subject based on the ideXlab platform.
-
A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases
Advances in therapy, 2015Co-Authors: Eleni Vangeli, Savita Bakhshi, Anna Baker, Abigail Fisher, Delaney Bucknor, Ulrich Mrowietz, Andrew J. K. Östör, Laurent Peyrin-biroulet, Ana P. Lacerda, John WeinmanAbstract:Background Non-Adherence impacts negatively on patient health outcomes and has associated economic costs. Understanding drivers of Treatment Adherence in immune-mediated inflammatory diseases is key for the development of effective strategies to tackle non-Adherence.
-
patients beliefs about prescribed medicines and their role in Adherence to Treatment in chronic physical illness
Journal of Psychosomatic Research, 1999Co-Authors: Rob Horne, John WeinmanAbstract:Abstract The aim of this cross-sectional study was to quantify patients' personal beliefs about the necessity of their prescribed medication and their concerns about taking it and to assess relations between beliefs and reported Adherence among 324 patients from four chronic illness groups (asthma, renal, cardiac, and oncology). The findings revealed considerable variation in reported Adherence and beliefs about medicines within and between illness groups. Most patients (89%) believed that their prescribed medication was necessary for maintaining health. However, over a third had strong concerns about their medication based on beliefs about the dangers of dependence or long-term effects. Beliefs about medicines were related to reported Adherence: higher necessity scores correlated with higher reported Adherence r=0.21, n =324, p and higher concerns correlated with lower reported Adherence r=0.33, n =324, p . For 17% of the total sample, concerns scores exceeded necessity scores and these patients reported significantly lower Adherence rates t=−4.28, p . Stepwise multiple linear regression analysis showed that higher reported Adherence rates were associated with higher necessity–concerns difference scores β =0.35, p , a diagnosis of asthma β =−0.31, p , a diagnosis of heart disease β =0.19, p , and age β =0.22, p . Gender, educational experience, or the number of prescribed medicines did not predict reported Adherence. Medication beliefs were more powerful predictors of reported Adherence than the clinical and sociodemographic factors, accounting for 19% of the explained variance in Adherence. These data were consistent with the hypothesis that many patients engage in an implicit cost–benefit analysis in which beliefs about the necessity of their medication are weighed against concerns about the potential adverse effects of taking it and that these beliefs are related to medication Adherence.
-
patients beliefs about prescribed medicines and their role in Adherence to Treatment in chronic physical illness
Journal of Psychosomatic Research, 1999Co-Authors: Rob Horne, John WeinmanAbstract:The aim of this cross-sectional study was to quantify patients' personal beliefs about the necessity of their prescribed medication and their concerns about taking it and to assess relations between beliefs and reported Adherence among 324 patients from four chronic illness groups (asthma, renal, cardiac, and oncology). The findings revealed considerable variation in reported Adherence and beliefs about medicines within and between illness groups. Most patients (89%) believed that their prescribed medication was necessary for maintaining health. However, over a third had strong concerns about their medication based on beliefs about the dangers of dependence or long-term effects. Beliefs about medicines were related to reported Adherence: higher necessity scores correlated with higher reported Adherence (r=0.21, n=324, p<0.01) and higher concerns correlated with lower reported Adherence (r=0.33, n=324, p<0.01). For 17% of the total sample, concerns scores exceeded necessity scores and these patients reported significantly lower Adherence rates (t=-4.28, p<0.001). Stepwise multiple linear regression analysis showed that higher reported Adherence rates were associated with higher necessity-concerns difference scores (beta=0.35, p<0.001), a diagnosis of asthma (beta= -0.31, p<0.001), a diagnosis of heart disease (beta=0.19, p<0.001), and age (beta=0.22, p<0.001). Gender, educational experience, or the number of prescribed medicines did not predict reported Adherence. Medication beliefs were more powerful predictors of reported Adherence than the clinical and sociodemographic factors, accounting for 19% of the explained variance in Adherence. These data were consistent with the hypothesis that many patients engage in an implicit cost-benefit analysis in which beliefs about the necessity of their medication are weighed against concerns about the potential adverse effects of taking it and that these beliefs are related to medication Adherence.
Gines Sanz - One of the best experts on this subject based on the ideXlab platform.
-
maximizing therapeutic envelope for prevention of cardiovascular disease role of polypill
Mount Sinai Journal of Medicine, 2012Co-Authors: Gines Sanz, Valentin FusterAbstract:Cardiovascular-disease prevention is often inadequate due to several factors. Lack of professional Adherence to guidelines, unaffordable medication, and lack of patients' Adherence to Treatment are the most important. It has been suggested that an affordable, fixed-dose combination drug containing evidence-based active compounds could improve cardiovascular prevention by improving patients' Adherence to Treatment. The available evidence suggests that the polypill strategy can achieve this objective and it will gain a place in the therapeutic armamentarium for the prevention of cardiovascular events in patients at high risk. Mt Sinai J Med 79:683–688, 2012. © 2012 Mount Sinai School of Medicine
-
the fixed dose combination drug for secondary cardiovascular prevention project improving equitable access and Adherence to secondary cardiovascular prevention with a fixed dose combination drug study design and objectives
American Heart Journal, 2011Co-Authors: Gines Sanz, Valentin Fuster, Luis A Guzman, Antonio Guglietta, Joan Albert Arnaiz, Felipe Martinez, Antonio Sarria, Maria Carla Roncaglioni, Kathryn TaubertAbstract:In spite of advances in prevention and Treatment, the burden of cardiovascular diseases is increasing. A fixed-dose combination (FDC) pill, or “polypill,” composed of evidence-based drugs has been proposed as a means of improving cardiovascular prevention by reducing cost and increasing patient Adherence to Treatment. The aim of the FOCUS project, funded by the 7th Framework Programme of the European Commission, is to characterize the factors that underlie inadequate secondary prevention and to test a new FDC. to achieve these goals, a 9-member consortium has been constituted, including institutions from Argentina, France, Italy, Spain, and Switzerland. FOCUS Phase-1 will examine factors potentially related to lack of adequate secondary prevention in 4,000 post–myocardial infarction (MI) patients and analyze the relationship between these factors and patient Treatment Adherence. Primary end points will be (1) the percentage of patients receiving aspirin, angiotensin-converting enzyme inhibitors, and statins and (2) Adherence to Treatment measured by the Morisky-Green test. FOCUS Phase-2 is a randomized trial that will compare Adherence to Treatment in 1,340 post–myocardial infarction patients either receiving an FDC comprising aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and simvastatin (40 mg) or receiving the same 3 drugs separately.
-
fixed dose combination therapy and secondary cardiovascular prevention rationale selection of drugs and target population
Nature Reviews Cardiology, 2009Co-Authors: Gines Sanz, Valentin FusterAbstract:Ischemic heart disease and stroke are the leading causes of death worldwide. A large proportion of individuals at high 10-year risk of a cardiovascular event live in low-income and middle-income countries, and the large majority of all cardiovascular events occur in developing countries. A large amount of evidence supports the use of pharmacological Treatment for the prevention of cardiovascular death in this population, including antiplatelet drugs, beta blockers, lipid-lowering agents and angiotensin-converting-enzyme inhibitors. However, the efficacy of cardiovascular prevention is hampered by several problems, including inadequate prescription of medication, poor Adherence to Treatment, limited availability of medications and unaffordable cost of Treatment. Here we examine the use of fixed-dose combination therapy (a 'polypill'), and how this therapy could improve Adherence to Treatment, reduce the cost and improve Treatment affordability in low-income countries.
Rob Horne - One of the best experts on this subject based on the ideXlab platform.
-
Adherence to Treatment in adolescents with cystic fibrosis the role of illness perceptions and Treatment beliefs
Journal of Pediatric Psychology, 2009Co-Authors: Romola S Bucks, Katharine Hawkins, Timothy Skinner, Sandra Horn, P Seddon, Rob HorneAbstract:Objectives This study was conducted to explore the relationships between illness perceptions, emotional representations, Treatment beliefs and reported Adherence in adolescents with cystic fibrosis (CF). Methods Thirty-eight adolescents completed questionnaires assessing their perceptions of CF, beliefs about prescribed Treatments and reported Adherence to chest physiotherapy, enzyme supplements, and antibiotics. Results Reported non-Adherence to chest physiotherapy was associated with the way in which patients judged their personal need for Treatment relative to their concerns about potential adverse effects. Patients reported strong doubts about the necessity of chest physiotherapy. Reported non-Adherence to antibiotics was related to doubts about the necessity of antibiotics, believing that CF is not amenable to Treatment control. Despite these beliefs about Treatment, participants perceived CF as a chronic condition. Conclusions The findings provide preliminary support for the self-regulatory model, using the necessity-concerns framework to operationalize Treatment beliefs, in explaining Adherence to Treatment in adolescents with CF.
-
patients beliefs about prescribed medicines and their role in Adherence to Treatment in chronic physical illness
Journal of Psychosomatic Research, 1999Co-Authors: Rob Horne, John WeinmanAbstract:Abstract The aim of this cross-sectional study was to quantify patients' personal beliefs about the necessity of their prescribed medication and their concerns about taking it and to assess relations between beliefs and reported Adherence among 324 patients from four chronic illness groups (asthma, renal, cardiac, and oncology). The findings revealed considerable variation in reported Adherence and beliefs about medicines within and between illness groups. Most patients (89%) believed that their prescribed medication was necessary for maintaining health. However, over a third had strong concerns about their medication based on beliefs about the dangers of dependence or long-term effects. Beliefs about medicines were related to reported Adherence: higher necessity scores correlated with higher reported Adherence r=0.21, n =324, p and higher concerns correlated with lower reported Adherence r=0.33, n =324, p . For 17% of the total sample, concerns scores exceeded necessity scores and these patients reported significantly lower Adherence rates t=−4.28, p . Stepwise multiple linear regression analysis showed that higher reported Adherence rates were associated with higher necessity–concerns difference scores β =0.35, p , a diagnosis of asthma β =−0.31, p , a diagnosis of heart disease β =0.19, p , and age β =0.22, p . Gender, educational experience, or the number of prescribed medicines did not predict reported Adherence. Medication beliefs were more powerful predictors of reported Adherence than the clinical and sociodemographic factors, accounting for 19% of the explained variance in Adherence. These data were consistent with the hypothesis that many patients engage in an implicit cost–benefit analysis in which beliefs about the necessity of their medication are weighed against concerns about the potential adverse effects of taking it and that these beliefs are related to medication Adherence.
-
patients beliefs about prescribed medicines and their role in Adherence to Treatment in chronic physical illness
Journal of Psychosomatic Research, 1999Co-Authors: Rob Horne, John WeinmanAbstract:The aim of this cross-sectional study was to quantify patients' personal beliefs about the necessity of their prescribed medication and their concerns about taking it and to assess relations between beliefs and reported Adherence among 324 patients from four chronic illness groups (asthma, renal, cardiac, and oncology). The findings revealed considerable variation in reported Adherence and beliefs about medicines within and between illness groups. Most patients (89%) believed that their prescribed medication was necessary for maintaining health. However, over a third had strong concerns about their medication based on beliefs about the dangers of dependence or long-term effects. Beliefs about medicines were related to reported Adherence: higher necessity scores correlated with higher reported Adherence (r=0.21, n=324, p<0.01) and higher concerns correlated with lower reported Adherence (r=0.33, n=324, p<0.01). For 17% of the total sample, concerns scores exceeded necessity scores and these patients reported significantly lower Adherence rates (t=-4.28, p<0.001). Stepwise multiple linear regression analysis showed that higher reported Adherence rates were associated with higher necessity-concerns difference scores (beta=0.35, p<0.001), a diagnosis of asthma (beta= -0.31, p<0.001), a diagnosis of heart disease (beta=0.19, p<0.001), and age (beta=0.22, p<0.001). Gender, educational experience, or the number of prescribed medicines did not predict reported Adherence. Medication beliefs were more powerful predictors of reported Adherence than the clinical and sociodemographic factors, accounting for 19% of the explained variance in Adherence. These data were consistent with the hypothesis that many patients engage in an implicit cost-benefit analysis in which beliefs about the necessity of their medication are weighed against concerns about the potential adverse effects of taking it and that these beliefs are related to medication Adherence.
Antje Lindenmeyer - One of the best experts on this subject based on the ideXlab platform.
-
interventions for improving Adherence to Treatment recommendations in people with type 2 diabetes mellitus
Cochrane Database of Systematic Reviews, 2005Co-Authors: Etienne Vermeire, Johan Wens, Paul Van Royen, Y Biot, Hilary Hearnshaw, Antje LindenmeyerAbstract:Background Research suggests Adherence to Treatment recommendations is low. In type 2 diabetes, which is a chronic condition slowly leading to serious vascular, nephrologic, neurologic and ophthalmological complications, it can be assumed that enhancing Adherence to Treatment recommendations may lead to a reduction of complications. Treatment regimens in type 2 diabetes are complicated, encompassing life-style adaptations and medication intake. Objectives to assess the effects of interventions for improving Adherence to Treatment recommendations in people with type 2 diabetes mellitus. Search strategy Studies were obtained from searches of multiple electronic bibliographic databases supplemented with hand searches of references. Date of last search: November 2002. Selection criteria Randomised controlled and controlled clinical trials, before-after studies and epidemiological studies, assessing changes in Adherence to Treatment recommendations, as defined in the objectives section, were included. Data collection and analysis Two teams of reviewers independently assessed the trials identified for inclusion. Three teams of two reviewers assessed trial quality and extracted data. The analysis for the narrative part was performed by one reviewer (EV), the meta-analysis by two reviewers (EV, JW). Main results Twentyone studies assessing interventions aiming at improving Adherence to Treatment recommendations, not to diet or exercise recommendations, in people living with type 2 diabetes in primary care, outpatient settings, community and hospital settings, were included. Outcomes evaluated in these studies were heterogeneous, there was a variety of Adherence measurement instruments. Nurse led interventions, home aids, diabetes education, pharmacy led interventions, adaptation of dosing and frequency of medication taking showed a small effect on a variety of outcomes including HbA1c. No data on mortality and morbidity, nor on quality of life could be found. Authors' conclusions Current efforts to improve or to facilitate Adherence of people with type 2 diabetes to Treatment recommendations do not show significant effects nor harms. The question whether any intervention enhances Adherence to Treatment recommendations in type 2 diabetes effectively, thus still remains unanswered.